Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong

[1]  R. Ribeiro,et al.  Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants , 2022, The New England journal of medicine.

[2]  M. Peiris,et al.  Replication of SARS-CoV-2 Omicron BA.2 variant in ex vivo cultures of the human upper and lower respiratory tract , 2022, eBioMedicine.

[3]  B. Cowling,et al.  Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case–control study , 2022, Emerging microbes & infections.

[4]  E. Lau,et al.  Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 Variant, Hong Kong, January–March 2022 , 2022, Emerging infectious diseases.

[5]  E. Lau,et al.  Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study , 2022, The Lancet Infectious Diseases.

[6]  G. Lozanski,et al.  Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants , 2022, The New England journal of medicine.

[7]  Fei Shao,et al.  BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.

[8]  S. Hoehl,et al.  Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes , 2022, Science Immunology.

[9]  M. V. van Zelm.  Immune memory to SARS-CoV-2 Omicron BA.1 breakthrough infections: To change the vaccine or not? , 2022, Science Immunology.

[10]  P. Klenerman,et al.  Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum , 2022, Cell.

[11]  M. Davenport,et al.  The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants , 2022, Immunity.

[12]  Qian Wang,et al.  SARS-CoV-2 Omicron BA.2.12.1, BA.4, and BA.5 subvariants evolved to extend antibody evasion , 2022, bioRxiv.

[13]  L. Walker,et al.  Recall of pre-existing cross-reactive B cell memory following Omicron BA.1 breakthrough infection , 2022, Science Immunology.

[14]  M. Nussenzweig,et al.  Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost , 2022, Nature.

[15]  Lauren E. W. Olsho,et al.  Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers , 2022, The New England journal of medicine.

[16]  Justine C. Williams,et al.  Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine , 2022, Cell.

[17]  C. Steves,et al.  Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study , 2022, The Lancet.

[18]  D. Barouch,et al.  Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants , 2022, The New England journal of medicine.

[19]  D. Montefiori,et al.  Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial , 2022, Nature Medicine.

[20]  Zhiwei Chen,et al.  Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong , 2022, eBioMedicine.

[21]  L. Blumberg,et al.  Clinical severity of COVID-19 patients admitted to hospitals during the Omicron wave in South Africa , 2022, medRxiv.

[22]  J. Zahradník,et al.  Virological characteristics of SARS-CoV-2 BA.2 variant , 2022, bioRxiv.

[23]  Liyuan Liu,et al.  Antibody evasion properties of SARS-CoV-2 Omicron sublineages , 2022, Nature.

[24]  S. Katikireddi,et al.  Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil , 2022, Nature Medicine.

[25]  J. Sidney,et al.  T Cell Responses to SARS-CoV-2. , 2022, Annual review of immunology.

[26]  L. Poon,et al.  SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo , 2022, Nature.

[27]  A. Sette,et al.  T cell responses to SARS-CoV-2 spike cross-recognize Omicron , 2022, Nature.

[28]  K. Spiess,et al.  Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households , 2022, medRxiv.

[29]  William F. Fadel,et al.  Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[30]  S. Schrag,et al.  Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. , 2022, JAMA.

[31]  K. To,et al.  Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron , 2022, Nature.

[32]  L. Poon,et al.  Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination , 2022, Nature Medicine.

[33]  S. Vermund,et al.  Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination , 2022, Nature Medicine.

[34]  P. Fournier,et al.  Characteristics of the first 1119 SARS‐CoV‐2 Omicron variant cases, in Marseille, France, November−December 2021 , 2022, Journal of medical virology.

[35]  Y. Poovorawan,et al.  COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron , 2022, medRxiv.

[36]  A. Sette,et al.  Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant , 2022, Nature Medicine.

[37]  Myung‐hee Lee,et al.  Clinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea , 2022, Journal of Korean medical science.

[38]  G. Screaton,et al.  Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study , 2022, The Lancet.

[39]  A. Walls,et al.  SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses , 2022, Cell.

[40]  O. Tsang,et al.  Vaccine‐breakthrough infection by the SARS‐CoV‐2 omicron variant elicits broadly cross‐reactive immune responses , 2022, Clinical and translational medicine.

[41]  C. Maslo,et al.  Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves. , 2021, JAMA.

[42]  O. Tsang,et al.  Vaccine-breakthrough infection by the SARS-CoV-2 Omicron variant elicits broadly cross-reactive immune responses , 2021 .

[43]  J. Bhiman,et al.  Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa , 2021, medRxiv.

[44]  Wen Zheng,et al.  Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials , 2021, The Lancet Infectious Diseases.

[45]  M. Sayegh,et al.  Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon , 2021, Vaccine.

[46]  Calliope A. Dendrou,et al.  An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease , 2021, Nature immunology.

[47]  A. Yılmaz,et al.  Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey , 2021, The Lancet.

[48]  L. Abu-Raddad,et al.  Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants , 2021, The New England journal of medicine.

[49]  D. Ho,et al.  Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies , 2021, Cell Host & Microbe.

[50]  A. Sette,et al.  Adaptive immunity to SARS-CoV-2 and COVID-19 , 2021, Cell.

[51]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[52]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[53]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[54]  C. Cordon-Cardo,et al.  Robust neutralizing antibodies to SARS-CoV-2 infection persist for months , 2020, Science.

[55]  Wenling Wang,et al.  Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial , 2020, The Lancet Infectious Diseases.

[56]  M. Nussenzweig,et al.  SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies , 2020, Nature.

[57]  F. Grosveld,et al.  SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model , 2020, bioRxiv.

[58]  Martin Linster,et al.  SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.

[59]  Nichollas E. Scott,et al.  Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19 , 2020, Nature Medicine.

[60]  O. Tsang,et al.  Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses , 2020, Immunity.

[61]  C. Scully,et al.  The Immune System: Basis of so much Health and Disease: 3. Adaptive Immunity. , 2017, Dental update.

[62]  Karlynn E. Neu,et al.  Low CD21 expression defines a population of recent germinal center graduates primed for plasma cell differentiation , 2017, Science Immunology.

[63]  Max E Valentinuzzi,et al.  SAFETY AND EFFICACY , 2010 .

[64]  OUP accepted manuscript , 2022, Clinical Infectious Diseases.

[65]  L. Gordon,et al.  EFFICACY AND SAFETY OF , 2004 .

[66]  Ying-hua Chen,et al.  Neutralizing antibodies , 2002, Immunologic research.

[67]  M. Eaman.  Immune system. , 2000, Nursing standard (Royal College of Nursing (Great Britain) : 1987).